Oramed Pharmaceuticals Past Earnings Performance
Past criteria checks 2/6
Oramed Pharmaceuticals's earnings have been declining at an average annual rate of -12.9%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been declining at an average rate of 3.8% per year. Oramed Pharmaceuticals's return on equity is 3.1%, and it has net margins of 412.3%.
Key information
-12.9%
Earnings growth rate
7.4%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | -3.8% |
Return on equity | 3.1% |
Net Margin | 412.3% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Aug 24Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
May 03Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Dec 22Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality
Sep 21Oramed to hand Korean rights for insulin capsule
Sep 09Oramed to report early-stage trial data for oral COVID-19 shot in 3Q
Jul 07Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?
Jun 12Oramed And Oral Insulin: Can This Small Company Really Do It?
Apr 14Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Feb 23Oramed And The Hurdles Of Developing Oral Insulin
Dec 23Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Nov 02Oramed: Prospects Still Remain Despite Merck-Ridgeback's Progress
Oct 04We Think Shareholders Will Probably Be Generous With Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Compensation
Aug 24Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
Jul 21Oramed reaches 50% enrollment in late-stage oral insulin study
Jun 08Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
Apr 06The Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Is Up 110% And Shareholders Are Boasting About It
Feb 12Oramed Pharmaceuticals EPS beats by $0.42, revenue in-line
Jan 14Why Oramed Pharmaceuticals' (NASDAQ:ORMP) CEO Pay Matters
Jan 08Oramed's obesity drug candidate shows decrease in glucose levels
Dec 23We Think Oramed Pharmaceuticals (NASDAQ:ORMP) Can Afford To Drive Business Growth
Dec 04Oramed launches late-stage NASH study with oral insulin
Dec 02Revenue & Expenses BreakdownBeta
How Oramed Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 1 | 6 | 8 | 9 |
30 Sep 23 | 2 | -16 | 9 | 14 |
30 Jun 23 | 3 | -20 | 11 | 19 |
31 Mar 23 | 3 | -30 | 11 | 26 |
31 Dec 22 | 3 | -37 | 16 | 28 |
30 Sep 22 | 3 | -46 | 20 | 32 |
30 Jun 22 | 3 | -46 | 19 | 33 |
31 Mar 22 | 3 | -40 | 18 | 27 |
31 Dec 21 | 3 | -35 | 13 | 27 |
30 Nov 21 | 3 | -25 | 8 | 22 |
31 Aug 21 | 3 | -22 | 6 | 21 |
31 May 21 | 3 | -18 | 4 | 18 |
28 Feb 21 | 3 | -15 | 4 | 15 |
31 Dec 20 | 3 | -22 | 5 | 21 |
30 Nov 20 | 3 | -15 | 4 | 14 |
31 Aug 20 | 3 | -12 | 4 | 10 |
31 May 20 | 3 | -11 | 4 | 9 |
29 Feb 20 | 3 | -13 | 4 | 11 |
30 Nov 19 | 3 | -13 | 4 | 11 |
31 Aug 19 | 3 | -14 | 4 | 14 |
31 May 19 | 3 | -15 | 4 | 14 |
28 Feb 19 | 3 | -15 | 4 | 14 |
30 Nov 18 | 3 | -14 | 4 | 14 |
31 Aug 18 | 2 | -13 | 4 | 12 |
31 May 18 | 2 | -12 | 4 | 12 |
28 Feb 18 | 2 | -10 | 3 | 10 |
30 Nov 17 | 2 | -10 | 3 | 10 |
31 Aug 17 | 2 | -10 | 3 | 10 |
31 May 17 | 2 | -13 | 2 | 11 |
28 Feb 17 | 2 | -13 | 2 | 10 |
30 Nov 16 | 1 | -11 | 2 | 8 |
31 Aug 16 | 1 | -11 | 2 | 8 |
31 May 16 | 0 | -8 | 3 | 6 |
29 Feb 16 | 0 | -8 | 3 | 6 |
30 Nov 15 | 0 | -8 | 3 | 5 |
31 Aug 15 | 0 | -7 | 3 | 5 |
31 May 15 | 0 | -7 | 3 | 4 |
28 Feb 15 | 0 | -7 | 3 | 4 |
30 Nov 14 | 0 | -6 | 3 | 4 |
31 Aug 14 | 0 | -6 | 3 | 3 |
31 May 14 | 0 | -5 | 2 | 3 |
28 Feb 14 | 0 | -4 | 2 | 3 |
30 Nov 13 | 0 | -4 | 2 | 3 |
31 Aug 13 | 0 | -4 | 2 | 2 |
Quality Earnings: ORMP has a large one-off gain of $16.4M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: ORMP became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ORMP has become profitable over the past 5 years, growing earnings by -12.9% per year.
Accelerating Growth: ORMP has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: ORMP has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.5%).
Return on Equity
High ROE: ORMP's Return on Equity (3.1%) is considered low.